Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18670803 | STABILIZED HEMAGGLUTININ (HA) TRIMERS AS INFLUENZA VACCINE ANTIGENS | May 2024 | August 2024 | Allow | 3 | 0 | 0 | No | No |
| 18512730 | SELF-REPLICATING RNA AND USES THEREOF | November 2023 | February 2024 | Allow | 3 | 0 | 0 | No | No |
| 18501578 | CHIMERIC INFLUENZA VACCINES | November 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18341590 | CORONAVIRUS VACCINE | June 2023 | October 2023 | Allow | 4 | 0 | 0 | No | No |
| 18336439 | ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME | June 2023 | July 2024 | Allow | 13 | 0 | 0 | No | No |
| 18334497 | ZIKA VIRUS VACCINE | June 2023 | July 2024 | Allow | 13 | 0 | 0 | No | No |
| 18330167 | ENGINEERED RED BLOOD CELLS HAVING RARE ANTIGEN PHENOTYPES | June 2023 | June 2024 | Allow | 12 | 0 | 0 | No | No |
| 18328528 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | June 2023 | August 2023 | Allow | 3 | 0 | 0 | No | No |
| 18328557 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease | June 2023 | August 2023 | Allow | 2 | 0 | 0 | No | No |
| 18038107 | DEVELOPING LATERAL FLOW IMMUNOCHROMATOGRAPHY (LFIA) PEPTIDE-BASED TEST STRIPS FOR RAPID DETECTION OF ANTIGENS AND ANTIBODIES AGAINST SPECIFIC ANTIGENS | May 2023 | January 2024 | Allow | 8 | 0 | 0 | No | No |
| 18318093 | OIL-BASED ADJUVANTS | May 2023 | June 2024 | Allow | 13 | 0 | 0 | No | No |
| 18316191 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | May 2023 | December 2023 | Allow | 8 | 1 | 0 | No | No |
| 18313017 | ADJUVANTED VACCINES CONTAINING MODIFIED S1 SPIKE PROTEIN OF SARS-COV-2 VARIANT C.1.2 FOR SUBCUTANEOUS ADMINISTRATION AND METHODS OF USE | May 2023 | October 2023 | Allow | 5 | 0 | 0 | No | No |
| 18312072 | EBIV NUCLEIC ACID COMPOSITION AND APPLICATION THEREOF | May 2023 | March 2024 | Allow | 10 | 0 | 0 | No | No |
| 18192274 | METHOD OF COMPACT PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | March 2023 | May 2024 | Allow | 13 | 0 | 0 | No | No |
| 18126140 | PROTEIN-BASED NANOPARTICLE VACCINE FOR METAPNEUMOVIRUS | March 2023 | August 2023 | Allow | 5 | 0 | 0 | No | No |
| 18125069 | Systems and Methods for Targeted Mass Inoculation | March 2023 | December 2023 | Allow | 8 | 1 | 1 | No | No |
| 18186874 | CORONAVIRUS DISEASE (COVID-19) VACCINE | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18178638 | ZIKA VIRUS VACCINE | March 2023 | June 2023 | Allow | 3 | 0 | 0 | No | No |
| 18177413 | METHOD FOR ADAPTING INFLUENZA VIRUSES TO VERO CELLS | March 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 18168396 | SUSPENSION SYSTEM FOR ADENO ASSOCIATED VIRUS PRODUCTION | February 2023 | May 2024 | Allow | 15 | 0 | 0 | No | No |
| 18165804 | MODIFIED NOROVIRUS VP1 PROTEINS AND VLPS COMPRISING MODIFIED NOROVIRUS VP1 PROTEINS | February 2023 | April 2024 | Allow | 14 | 0 | 0 | No | No |
| 18159827 | ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS | January 2023 | April 2024 | Allow | 14 | 0 | 0 | No | No |
| 18158800 | Combination Immunotherapy Compositions Against Cancer and Methods | January 2023 | May 2024 | Allow | 16 | 0 | 0 | No | No |
| 18099044 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | February 2024 | Allow | 12 | 0 | 0 | No | No |
| 18099035 | HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF | January 2023 | March 2024 | Allow | 14 | 0 | 0 | No | No |
| 18097004 | METHODS FOR DETECTING NOROVIRUS | January 2023 | April 2024 | Allow | 15 | 0 | 0 | No | No |
| 18150957 | MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY | January 2023 | February 2024 | Allow | 13 | 0 | 0 | No | No |
| 18151409 | VIRUS-LIKE PARTICLE (VLP)-BASED VACCINE AGAINST CVB4 | January 2023 | September 2023 | Allow | 8 | 1 | 1 | No | No |
| 18087772 | METHODS AND SYSTEMS FOR ANALYSIS OF SAMPLES CONTAINING PARTICLES USED FOR GENE DELIVERY | December 2022 | July 2023 | Allow | 7 | 0 | 1 | No | No |
| 18086594 | REPLICATION COMPETENT ATTENUATED VACCINIA VIRUSES WITH DELETION OF THYMIDINE KINASE WITH AND WITHOUT THE EXPRESSION OF HUMAN FLT3L OR GM-CSF FOR CANCER IMMUNOTHERAPY | December 2022 | January 2024 | Allow | 13 | 0 | 0 | No | No |
| 18067525 | EPITOPE FOCUSING BY VARIABLE EFFECTIVE ANTIGEN SURFACE CONCENTRATION | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18065172 | ANTIBODY NEUTRALIZING HUMAN RESPIRATORY SYNCYTIAL VIRUS | December 2022 | January 2024 | Allow | 13 | 0 | 0 | No | No |
| 18059171 | MODIFIED S1 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN | November 2022 | December 2023 | Allow | 13 | 0 | 0 | No | No |
| 17987973 | RNA SEPARATION AND RELATED TECHNIQUES FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES | November 2022 | May 2023 | Allow | 6 | 1 | 0 | No | No |
| 17998208 | CHIMERIC INFLUENZA VACCINES | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 18050027 | EXTRACELLULAR VESICLES FOR VACCINE DELIVERY | October 2022 | January 2024 | Allow | 15 | 0 | 1 | No | No |
| 18049296 | TREATMENT OF GLYCOGEN STORAGE DISEASE III | October 2022 | October 2024 | Abandon | 24 | 1 | 0 | No | No |
| 17996919 | DIAGNOSTIC CONTROL COMPOSITIONS | October 2022 | March 2023 | Allow | 5 | 0 | 0 | No | No |
| 17938271 | PARVOVIRUS STRUCTURAL PROTEIN FOR THE TREATMENT OF AUTOIMMUNE DISEASES | October 2022 | December 2023 | Allow | 14 | 0 | 0 | No | No |
| 17935024 | RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL | September 2022 | November 2023 | Allow | 14 | 0 | 0 | No | No |
| 17931887 | METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION | September 2022 | February 2024 | Allow | 17 | 0 | 0 | No | No |
| 17930166 | AAV CAPSIDS IDENTIFIED BY IN VIVO LIBRARY SELECTION | September 2022 | April 2024 | Allow | 19 | 1 | 0 | No | No |
| 17818440 | PLUG FLOW TUBULAR BIOREACTOR, SYSTEM CONTAINING THE SAME AND METHOD FOR PRODUCTION OF VIRUS | August 2022 | June 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17818314 | TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES | August 2022 | March 2024 | Allow | 20 | 1 | 0 | No | No |
| 17817708 | CORONAVIRUS DISEASE (COVID-19) VACCINE | August 2022 | December 2022 | Allow | 5 | 0 | 0 | No | No |
| 17815065 | ADENO-ASSOCIATED VIRUS VECTOR VARIANTS FOR HIGH EFFICIENCY GENOME EDITING AND METHODS THEREOF | July 2022 | November 2023 | Allow | 15 | 0 | 0 | No | No |
| 17814871 | INFLUENZA VIRUS VACCINES AND USES THEREOF | July 2022 | November 2023 | Allow | 15 | 0 | 0 | No | No |
| 17814097 | NUCLEIC ACID DETECTION USING TYPE III CRISPR COMPLEX | July 2022 | February 2023 | Allow | 6 | 0 | 0 | No | No |
| 17813200 | INFLUENZA VIRUS REPLICATION FOR VACCINE DEVELOPMENT | July 2022 | June 2024 | Allow | 23 | 1 | 0 | No | No |
| 17863603 | METHOD OF COMPACT PEPTIDE VACCINES USING RESIDUE OPTIMIZATION | July 2022 | December 2022 | Allow | 5 | 0 | 0 | No | No |
| 17811479 | CULTIVATION OF HUMAN NOROVIRUSES | July 2022 | October 2023 | Allow | 16 | 0 | 0 | No | No |
| 17855612 | RAPID DETECTION TESTS WITH PRELOADED DETECTION PARTICLES | June 2022 | April 2023 | Allow | 9 | 1 | 1 | No | No |
| 17851905 | VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES | June 2022 | March 2024 | Allow | 21 | 1 | 0 | No | No |
| 17848637 | RSV VACCINES AND METHODS OF PRODUCTION AND USE THEREOF | June 2022 | September 2023 | Allow | 15 | 0 | 0 | No | No |
| 17837861 | UNIVERSAL VACCINES AGAINST IMMUNOGENS OF PATHOGENIC ORGANISMS THAT PROVIDE ORGANISM-SPECIFIC AND CROSS-GROUP PROTECTION | June 2022 | March 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17832664 | CORONAVIRUS VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | June 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17827256 | ANTIGENS OF BETA-CORONAVIRUSES, PREPARATION METHODS AND USES THEREOF | May 2022 | November 2022 | Allow | 6 | 1 | 0 | No | No |
| 17751208 | METHODS AND COMPOSITIONS FOR A UNIVERSAL AND LONG-LASTING VACCINE | May 2022 | November 2022 | Allow | 6 | 0 | 0 | No | No |
| 17732127 | VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE | April 2022 | September 2023 | Allow | 16 | 0 | 0 | No | No |
| 17732076 | VACCINE FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF A DISEASE | April 2022 | February 2024 | Allow | 22 | 1 | 0 | No | No |
| 17726567 | WHOLE AVIAN-ORIGIN REVERSE GENETIC SYSTEM AND RECOMBINANT H5N2 SUBTYPE AVIAN INFLUENZA VIRUS, VACCINE AND USES THEREOF | April 2022 | August 2022 | Allow | 4 | 0 | 0 | No | No |
| 17727405 | COMPOSITION FOR REGULATING PRODUCTION OF RIBONUCLEIC ACID | April 2022 | September 2022 | Allow | 4 | 0 | 0 | No | No |
| 17718596 | AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS) | April 2022 | July 2022 | Allow | 3 | 0 | 0 | No | No |
| 17718056 | ENGINEERED INFLUENZA ANTIGENIC POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS THEREOF | April 2022 | September 2023 | Allow | 17 | 0 | 0 | No | No |
| 17711012 | EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 | March 2022 | July 2022 | Allow | 4 | 0 | 0 | No | No |
| 17707940 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | March 2022 | February 2023 | Allow | 10 | 1 | 1 | No | No |
| 17700250 | METHOD OF ASSESSING RISK OF PML | March 2022 | October 2023 | Allow | 19 | 0 | 0 | No | No |
| 17698205 | FELINE LEUKEMIA VIRUS VACCINE | March 2022 | April 2024 | Allow | 25 | 1 | 0 | No | No |
| 17695898 | SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF | March 2022 | June 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17695994 | RNA SEPARATION AND RELATED TECHNIQUES FOR DETERMINING VIRUSES SUCH AS CORONAVIRUSES | March 2022 | November 2022 | Allow | 8 | 1 | 0 | No | No |
| 17694440 | ZIKA VIRUS CHIMERIC POLYEPITOPE COMPRISING NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION | March 2022 | September 2023 | Allow | 18 | 0 | 0 | No | No |
| 17684341 | VIRUS-LIKE PARTICLES FOR PREVENTING THE SPREADING AND LOWERING THE INFECTION RATE OF VIRUSES | March 2022 | December 2022 | Allow | 9 | 1 | 1 | No | No |
| 17679356 | ADENOVIRAL VECTORS ENCODING HEPATITIS B VIRAL ANTIGENS FUSED TO HERPES VIRUS GLYCOPROTEIN D AND METHODS OF USING THE SAME | February 2022 | August 2023 | Allow | 18 | 0 | 0 | No | No |
| 17675297 | INFLUENZA VIRUS VECTORS AND USES THEREFOR | February 2022 | January 2024 | Allow | 23 | 1 | 0 | No | No |
| 17669979 | SPECIFIC ANTIGEN SEQUENCES FOR COVID-19 AND METHODS OF USE | February 2022 | November 2023 | Allow | 21 | 0 | 0 | No | No |
| 17587376 | Adenoviral Vector | January 2022 | December 2023 | Allow | 23 | 1 | 0 | No | No |
| 17585022 | METHODS AND COMPOSITIONS FOR TREATING CORONAVIRUS INFECTIONS | January 2022 | July 2023 | Allow | 18 | 1 | 0 | No | No |
| 17583088 | INFLUENZA VIRUS HEMAGGLUTININ PROTEINS AND USES THEREOF | January 2022 | May 2023 | Allow | 16 | 0 | 0 | No | No |
| 17578939 | MUTATIONS THAT CONFER GENETIC STABILITY TO GENES IN INFLUENZA VIRUSES | January 2022 | December 2023 | Abandon | 23 | 1 | 0 | No | No |
| 17567411 | COMPOSITIONS, KITS AND METHODS FOR DETECTION OF VIRAL SEQUENCES | January 2022 | April 2024 | Allow | 27 | 1 | 0 | No | No |
| 17565332 | VACCINIA VIRUS MUTANTS USEFUL FOR CANCER IMMUNOTHERAPY | December 2021 | September 2023 | Allow | 20 | 1 | 0 | No | No |
| 17645556 | Methods and Compositions for Heterologous repRNA Immunizations | December 2021 | December 2023 | Allow | 24 | 1 | 0 | No | No |
| 17557180 | Compositions and Methods for Identifying and Sorting Antigen-Specific B Cells | December 2021 | April 2023 | Allow | 16 | 0 | 0 | No | No |
| 17554830 | METHODS AND SYSTEMS FOR ANALYSIS OF SAMPLES CONTAINING PARTICLES USED FOR GENE DELIVERY | December 2021 | August 2022 | Allow | 8 | 0 | 1 | No | No |
| 17548721 | ZIKA VIRUS VACCINE | December 2021 | May 2023 | Allow | 17 | 0 | 0 | No | No |
| 17643606 | Poxvirus Vectors Encoding HIV Antigens, and Methods of Use Thereof | December 2021 | March 2023 | Allow | 16 | 0 | 0 | No | No |
| 17537199 | COMPOSITIONS AND METHODS FOR INDUCING ESR1, PI3K, HER2, AND HER3 IMMUNE RESPONSES | November 2021 | March 2022 | Allow | 4 | 0 | 0 | No | No |
| 17535309 | RECOMBINANT POLYPEPTIDES CONTAINING AT LEAST ONE IMMUNOGENIC FRAGMENT AND ANTIBODY FC REGION AND USES THEREOF | November 2021 | February 2022 | Allow | 3 | 0 | 0 | No | No |
| 17534032 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF | November 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17534256 | DNA VACCINE FOR HUMAN PAPILLOMAVIRUS AND METHOD FOR USING THE SAME | November 2021 | August 2023 | Allow | 21 | 0 | 0 | No | No |
| 17523174 | Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus F proteins and their use | November 2021 | April 2023 | Allow | 17 | 0 | 0 | No | No |
| 17518268 | MODIFIED VIRUSES | November 2021 | December 2023 | Allow | 26 | 1 | 0 | No | No |
| 17517343 | METHODS AND COMPOSITION FOR GENE DELIVERY USING AN ENGINEERED VIRAL PARTICLE | November 2021 | March 2023 | Allow | 17 | 0 | 0 | No | No |
| 17512902 | NOVEL SARS-COV-2 ANTIGENS AND USES THEREOF | October 2021 | August 2023 | Allow | 21 | 0 | 0 | No | No |
| 17505496 | HYBRID ALPHAVIRUS-SARS-COV-2 PARTICLE AND METHODOLOGY OF MAKING AND USING SAME | October 2021 | June 2022 | Allow | 7 | 1 | 1 | No | No |
| 17505466 | VIRUS-INSPIRED COMPOSITIONS AND METHODS OF REDIRECTING PREEXISTING IMMUNE RESPONSES USING THE SAME FOR TREATMENT OF CANCER | October 2021 | August 2023 | Allow | 21 | 1 | 0 | No | No |
| 17500750 | METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS | October 2021 | March 2023 | Allow | 17 | 0 | 0 | No | No |
| 17490498 | ANTIGEN SPECIFIC MULTI EPITOPE-BASED ANTI-INFECTIVE VACCINES | September 2021 | December 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17489572 | CORONAVIRUS VACCINE COMPOSITIONS, METHODS, AND USES THEREOF | September 2021 | February 2022 | Allow | 5 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHESTNUT, BARRY A.
With a 42.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHESTNUT, BARRY A works in Art Unit 1648 and has examined 915 patent applications in our dataset. With an allowance rate of 76.0%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner CHESTNUT, BARRY A's allowance rate of 76.0% places them in the 34% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHESTNUT, BARRY A receive 1.35 office actions before reaching final disposition. This places the examiner in the 28% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by CHESTNUT, BARRY A is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +3.0% benefit to allowance rate for applications examined by CHESTNUT, BARRY A. This interview benefit is in the 22% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 25.5% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 32.8% of cases where such amendments are filed. This entry rate is in the 40% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 83.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 78.8% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 51.4% are granted (fully or in part). This grant rate is in the 63% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.